Sign in

    Amgen Inc (AMGN)

    Financials

    Updated May 3, 2025, 1:18 AM UTC
    Income Statement - MetricFY 2013Q1 2014Q2 2014Q3 2014Q4 2014FY 2014Q1 2015Q2 2015Q3 2015Q4 2015FY 2015Q1 2016Q2 2016Q3 2016Q4 2016FY 2016Q1 2017Q2 2017Q3 2017Q4 2017FY 2017Q1 2018Q2 2018Q3 2018Q4 2018FY 2018Q1 2019Q2 2019Q3 2019Q4 2019FY 2019Q1 2020Q2 2020Q3 2020Q4 2020FY 2020Q1 2021Q2 2021Q3 2021Q4 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025
    Product sales (USD, millions)7,833.0026,9107,1188,041.008,151.008,716.0032,0267,873
    Other revenues (USD, millions)363.001,280329347.00352.00370.001,398276
    Total revenues (USD, millions)8,196.0028,1907,4478,388.008,503.009,086.0033,4248,149
    Cost of sales (USD, millions)3,112.008,4513,236.003,310.003,112.0012,8582,968
    Research and development (USD, millions)1,534.004,7841,3431,447.001,450.001,724.005,9641,486
    Selling, general and administrative (USD, millions)2,274.006,1791,8081,785.001,625.001,878.007,0961,687
    Other operating expenses (USD, millions)5.0087910511.0071.0061.00248830
    Total operating expenses (USD, millions)6,925.0020,2936,4566,479.006,456.006,775.0026,1666,971
    Operating income (USD, millions)1,271.007,8971,909.002,047.002,311.007,2581,178
    Interest expense, net (USD, millions)(821.00)(2,875)(824)(808.00)(776.00)(747.00)(3,155)(723)
    Other income (expense), net (USD, millions)402.002,833(307.00)1,830.00(782.00)5061,518
    Income before income taxes (USD, millions)852.007,855(68)794.003,101.00782.004,6091,973
    Provision for income taxes (USD, millions)85.001,1384548.00271.00155.00519243
    Net income (USD, millions)767.006,717746.002,830.00627.004,0901,730
    Basic earnings per share (USD)1.4412.561.395.271.177.623.22
    Diluted earnings per share (USD)1.4312.49(0.21)1.385.231.167.563.20
    Basic weighted-average shares (millions)0.005355361.000.000.00537538
    Diluted weighted-average shares (millions)0.005385365.000.000.00541541
    Balance Sheet - MetricFY 2013Q1 2014Q2 2014Q3 2014Q4 2014FY 2014Q1 2015Q2 2015Q3 2015Q4 2015FY 2015Q1 2016Q2 2016Q3 2016Q4 2016FY 2016Q1 2017Q2 2017Q3 2017Q4 2017FY 2017Q1 2018Q2 2018Q3 2018Q4 2018FY 2018Q1 2019Q2 2019Q3 2019Q4 2019FY 2019Q1 2020Q2 2020Q3 2020Q4 2020FY 2020Q1 2021Q2 2021Q3 2021Q4 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025
    Cash and Cash Equivalents (USD, millions)10,94410,9449,7089,3019,01111,9738,810
    Trade Receivables, Net (USD, millions)7,2687,2686,7766,9347,3176,7826,7828,132
    Inventories (USD, millions)9,5189,5188,7247,9957,3626,9986,9986,729
    Other Current Assets (USD, millions)2,6022,6022,8212,9763,0763,2773,2773,258
    Total Current Assets (USD, millions)30,33230,33228,02927,20626,76629,03029,03026,929
    Property, Plant and Equipment, Net (USD, millions)5,9415,9416,0026,0976,1566,5436,5436,681
    Intangible Assets, Net (USD, millions)32,64132,64131,37230,17228,92027,69927,69925,724
    Goodwill (USD, millions)18,62918,62918,57018,61618,65818,63718,63718,645
    Other Noncurrent Assets (USD, millions)9,6119,6119,0078,81610,3839,9309,93011,388
    Total Assets (USD, millions)97,15497,15492,98090,90790,88391,83989,367
    Current Portion of Long-Term Debt (USD, millions)1,4431,4433,9593,5443,5503,5503,368
    Total Current Liabilities (USD, millions)18,39218,39219,71421,51720,31223,09923,09923,008
    Long-Term Debt (USD, millions)63,17063,17060,06157,11756,85456,54956,54954,013
    Long-Term Deferred Tax Liabilities (USD, millions)2,3542,3541,8621,7801,7111,6161,6161,510
    Long-Term Tax Liabilities (USD, millions)4,6804,6803,9642,2052,2802,3492,3492,419
    Other Noncurrent Liabilities (USD, millions)2,3262,3262,3572,3632,1992,3492,3492,210
    Total Stockholders’ Equity (USD, millions)6,2326,2325,0225,9257,5275,8775,8776,207
    Total Liabilities and Stockholders’ Equity (USD, millions)97,15497,15492,98090,90790,88391,83991,83989,367
    Cash Flow - MetricFY 2013Q1 2014Q2 2014Q3 2014Q4 2014FY 2014Q1 2015Q2 2015Q3 2015Q4 2015FY 2015Q1 2016Q2 2016Q3 2016Q4 2016FY 2016Q1 2017Q2 2017Q3 2017Q4 2017FY 2017Q1 2018Q2 2018Q3 2018Q4 2018FY 2018Q1 2019Q2 2019Q3 2019Q4 2019FY 2019Q1 2020Q2 2020Q3 2020Q4 2020FY 2020Q1 2021Q2 2021Q3 2021Q4 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025
    Net cash provided by operating activities (USD, millions)538.008,4716892,459.003,571.0011,4901,391
    Net cash used in investing activities (USD, millions)--(217)(217.00)(210.00)(402.00)(1,046)(447)
    Purchases of property, plant and equipment (USD, millions)(249.00)(1,112)(230)(238.00)(257.00)(371.00)(1,096)(411)
    Net cash (used in) provided by financing activities (USD, millions)2,754.0021,048(1,708)(2,649.00)(3,651.00)(1,407.00)(4,107)
    Increase (decrease) in cash and cash equivalents (USD, millions)(23,797.00)3,315(1,236)(407.00)(290.00)1,029(3,163)
    Cash and cash equivalents at beginning of year (USD, millions)7,6297,62910,94410,94410,94410,94410,94411,973
    Cash and cash equivalents at end of year (USD, millions)10,94410,9449,7089,3019,01111,97311,9738,810
    Revenue by Segment - in Millions of USDFY 2013Q1 2014Q2 2014Q3 2014Q4 2014FY 2014Q1 2015Q2 2015Q3 2015Q4 2015FY 2015Q1 2016Q2 2016Q3 2016Q4 2016FY 2016Q1 2017Q2 2017Q3 2017Q4 2017FY 2017Q1 2018Q2 2018Q3 2018Q4 2018FY 2018Q1 2019Q2 2019Q3 2019Q4 2019FY 2019Q1 2020Q2 2020Q3 2020Q4 2020FY 2020Q1 2021Q2 2021Q3 2021Q4 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025
    Prolia1,1074,0489991,1651,0451,1654,3741,099
    ENBREL1,0153,6975679098251,0153,316510
    XGEVA5272,1125615625415612,225566
    Repatha4171,6355175325676062,222656
    Otezla6292,1883945445646242,126437
    TEPEZZA-448424479488461,851381
    EVENITY3181,1603423913994311,563442
    KYPROLIS351,4033763773783721,503324
    Nplate3861,4773173464563371,456313
    Aranesp3191,3623493483373081,342340
    KRYSTEXXA-2722352943103461,185236
    BLINCYTO-8612442643273811,216370
    Vectibix-9842472702822461,045267
    TEZSPIRE--173234269296972285
    Sensipar/Mimpara--------
    EPOGEN--------
    Neulasta--------
    - NEUPOGEN--------
    Other products25,2631,3731,3261,3631,5685,6301,647
    Total Product Sales7,83326,9107,1188,0418,1518,71632,0267,873
    Other Revenues3631,280329347352371,398276
    Total Revenues8,19628,1907,4478,3888,5039,08633,4248,149
    Revenue by Geography - in Millions of USDFY 2013Q1 2014Q2 2014Q3 2014Q4 2014FY 2014Q1 2015Q2 2015Q3 2015Q4 2015FY 2015Q1 2016Q2 2016Q3 2016Q4 2016FY 2016Q1 2017Q2 2017Q3 2017Q4 2017FY 2017Q1 2018Q2 2018Q3 2018Q4 2018FY 2018Q1 2019Q2 2019Q3 2019Q4 2019FY 2019Q1 2020Q2 2020Q3 2020Q4 2020FY 2020Q1 2021Q2 2021Q3 2021Q4 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025
    U.S. Product Sales5,8719,2724,9735,8405,9796,50923,3015,662
    ROW Product Sales1,9637,6382,1452,2012,1722,2078,7252,211
    Total Product Sales7,83326,9107,1188,0418,1518,71632,0267,873
    U.S. Other Revenues-534----562-
    ROW Other Revenues-746----836-
    Total Other Revenues3631,280329347352371,398276
    Total U.S. Revenues-19,806----23,8635,662 (Product Sales) + N/A (Other Revenues)
    Total ROW Revenues-8,384----9,5612,211 (Product Sales) + N/A (Other Revenues)
    Total Revenues8,19628,1907,4478,3888,5039,08633,4248,149
    KPIs - Metric (Unit, Scale)FY 2013Q1 2014Q2 2014Q3 2014Q4 2014FY 2014Q1 2015Q2 2015Q3 2015Q4 2015FY 2015Q1 2016Q2 2016Q3 2016Q4 2016FY 2016Q1 2017Q2 2017Q3 2017Q4 2017FY 2017Q1 2018Q2 2018Q3 2018Q4 2018FY 2018 (%)Q1 2019 (%)Q2 2019 (%)Q3 2019 (%)Q4 2019FY 2019 (%)Q1 2020 (%)Q2 2020 (%)Q3 2020 (%)Q4 2020FY 2020Q1 2021Q2 2021Q3 2021Q4 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025
    Volume growth for Repatha (percentage)--444641---
    Volume growth for Otezla (percentage)---2%5%---
    Volume growth for Prolia (percentage)--------